Differential expression of potential biomarkers of oral squamous cell carcinoma development

Research output: Contribution to journalArticlepeer-review


  • Paola Fernandes Pansini
  • Isabella Bittencourt do Valle
  • Thabata Coeli Dias Damasceno
  • Priscila Marinho de Abreu
  • Anna Clara Gregório Có
  • Rossana Verónica Mendoza López
  • Jeferson Lenzi
  • Ricardo Mai Rocha
  • Evandro Duccini Souza
  • Maria Paula Curado
  • José Roberto Vasconcelos de Podestá
  • Sandra Ventorin von Zeidler

External organisations

  • Universidade Federal do Espírito santo
  • Instituto do Câncer do Estado de São Paulo
  • Hospital Santa Rita de Cássia
  • Centro Internacional de Pesquisa, AC Camargo Cancer Center
  • Universidade Federal de Minas Gerais


To evaluate molecular epithelial changes, we investigated whether a profile of survivin, cyclin dependent kinase inhibitor 2A (CDKN2A), epidermal growth factor receptor (EGFR), polo like kinase 1 (PLK1), p63, p40 (Δnp63 isoform), cyclin D1 (CCND1) and BCL2 apoptosis regulator (BCL2) proteins could predict malignant transformation. Different tissue segments (tumor adjacent epithelium; dysplasia and tumor) from a total of 109 patients were analyzed by immunohistochemistry. An increased expression of survivin (p < 0.001), PLK1 (p = 0.001), and p63 (p < 0.001) in parallel to reduced immunostaining of p40 (p < 0.001) and BCL2 (p = 0.029) was observed among the tissue segments analyzed. Our study revealed that survivin, PLK1, p63, p40 and BCL2 play a role in oral tumorigenesis and represent promising biomarkers able to recognize mesenchymal phenotype induction in the transition from nonmalignant cells to tumor cells. These results reveals critical interaction between survivin, PLK1, p63, p40 promising proteins during invasive carcinoma development.

Bibliographic note

Funding Information: The authors would like to thank the Head and Neck Division teams of the Santa Rita de Cássia Hospital, Cassiano Antônio Moraes University Hospital, and University Hospitals Coventry and Warwickshire NHS Trust. This study was financed by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001 and FAPES/CNPq/Decit-SCTIE-MS/SESA – PPSUS, Espírito Santo (Protocol number 83139940/2018).


Original languageEnglish
JournalHead and Neck Pathology
Early online date11 Apr 2021
Publication statusE-pub ahead of print - 11 Apr 2021


  • Biomarkers, Dysplasia, Immunohistochemistry, Oral cancer, Progression, Tumor

Sustainable Development Goals